Johnson & Johnson MedTech is accelerating its research and innovation footprint in Ireland with a major expansion at its Galway site, a centre of excellence for neurovascular disease research. The facility, part of the company’s Cerenovus unit, develops stroke treatment devices and supports the Neuro Thromboembolic Initiative, which focuses on unmet needs in acute ischemic and hemorrhagic stroke.

The investment enhances the site’s capabilities in stroke-specific and liquid embolic procedural research, while broadening the scope to include chronic subdural hematoma and other neurovascular conditions. The move also strengthens the local engineering and scientific talent base, enabling faster development of new treatment solutions and reinforcing Ireland’s role in J&J MedTech’s global innovation network.

Since establishing a presence in Galway in 2017, J&J MedTech has steadily expanded operations, including the opening of a state-of-the-art innovation centre in 2022. The latest announcement coincides with the inaugural meeting of the company’s Neurovascular Global Scientific Advisory Board in Galway, signalling a strategic focus on deepening scientific leadership and collaboration.

Michael Gilvarry, head of R&D for J&J MedTech Neurovascular, highlighted that the Galway workforce is applying advanced engineering and scientific knowledge to address life-threatening neurovascular conditions. Michael Lohan, CEO of IDA Ireland, underscored Galway’s status as a European medtech hub and emphasised the project’s alignment with Ireland’s Adapt Intelligently strategy, which prioritises innovation-driven growth and high-skilled employment.

This expansion reflects a sustained commitment to advancing neurovascular treatment solutions while reinforcing Ireland’s position as a global centre for medical technology innovation.

Discover the full details on how J&J MedTech is shaping the future of stroke care in Ireland.